Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

Expert Review of Clinical Pharmacology

Volumn 2, Issue 6, 2009, Pages 589-600

  Christopher, Ronald ^a   Karim, Aziz ^b  

^a Takeda San Diego Inc   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Alogliptin; Diabetes; Dipeptidyl peptidase 4; Incretin hormones

Indexed keywords

ALOGLIPTIN; ATORVASTATIN; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; ETHINYLESTRADIOL; FLUCONAZOLE; GEMFIBROZIL; GLIBENCLAMIDE; KETOCONAZOLE; METFORMIN; NORETHISTERONE; PIOGLITAZONE; PLACEBO; WARFARIN;

AGE DISTRIBUTION; ANGINA PECTORIS; ARTHRALGIA; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FACIAL NERVE PARALYSIS; FATIGUE; FOOD; FOOD DRUG INTERACTION; HOT FLUSH; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MYCOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PHARMACODYNAMICS; RACE DIFFERENCE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SYNCOPE; THORAX PAIN; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 70549085872     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.45     Document Type: Review

References (45)

1. Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of Type 2 diabetes? Diabetes Metab. 33(1), 3-12 (2007). • Demonstrates that diabetes is a disease with considerable comorbidities and mortality.
2. Giorgino F, Laviola L, Leonardini A. Pathophysiology of Type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes. Res. Clin. Pract. 68S1, S22-S29 (2005). (Pubitemid 40805488)
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 27(5), 1047-1053 (2004).
4. Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab. 33, 231-244 (2007). • Demonstrates the need for newer and better antidiabetic mediations. (Pubitemid 47440080)
5. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 31(12), 1-11 (2008).
6. American Diabetes Association: Standards of medical care in diabetes - 2008 (position statement). Diabetes Care 31(Suppl. 1), S12-S54 (2008).
7. Haberman AB. Addressing unmet Type 2 diabetes needs. Gen. Engineering Biotechnol. News 28(1), 34-35 (2008).
8. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for Type 2 diabetes mellitus. Pharmacotherapy 25(6), 810-816 (2005).
9. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373, 473-481 (2008).
10. Bloomgren G, Bore D, Patterson R, Noei R, Braun D, Seeger J. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug inhibitors: a retrospective, cohort study. Presented at: American Diabetes Association 69th Scientific Sessions. New Orleans, LA, USA, 5-9 June 2009. Diabetes 58(Suppl. 1), (2009) (Abstract 158-OR).
11. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of Type 2 diabetes. Curr. Opin. Investig. Drugs 9(4), 402-413 (2008).
12. Vollmer K, Holst JJ, Baller B et al. Predicators of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57, 678-687 (2008).
13. Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple dose study in adult patients with Type 2 diabetes. Clin. Ther. 30(3), 499-512 •• First clinical trial performed in Type 2 diabetes patients.
14. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 30(3), 513-527 (2008). •• Demonstrates the pharmacokinetics and pharmacodynamics of alogliptin.
15. Karim A, Bridson WE, Fleck P, Schuster S, Zhang W, Mekki Q. Disposition of the dipeptidyl peptidase-4 inhibitor [14C] alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects. AAPS J. 9(Suppl. 2), (2007). •• Demonstrates the metabolism of alogliptin.
16. Karim A, Fleck P, Harris S, Schuster J, Zhang W, Mekki Q. Effect of fluconazole, ketoconazole, and gemfibrozil on the pharmacokinetics of alogliptin benzoate (SYR-322) in healthy subjects. Presented at: 36th Meeting of the American College of Clinical Pharmacology. San Francisco, CA, USA, 9-11 September 2007. J. Clin. Pharmacol. 47(9), 1207, (2007) (Abstract 105).
17. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, for the Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract. 36(1), 46-55 (2009).
18. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with Type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6 June-10 June 2008. Diabetes 57(Suppl. 1), (2008) (Abstract 478-P).
19. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; on behalf of the Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes. Obes. Metab. 11, 167-176 (2009).
20. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, on behalf of the Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with Type 2 diabetes and inadequate glycemic control. Diabetes Care 31(12), 2315-2317 (2008). • Demonstrates that alogliptin is efficacious as a monotherapy in a Phase III study.
21. Rosenstock J, Rendell M, Gross JL, Fleck P, Wilson C, Mekki Q. Alogliptin added to insulin therapy in patients with Type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10 June 2008. Diabetes 57(Suppl. 1), (2008) (Abstract 444-P).
22. Feng J, Zhang Z, Wallace MB et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 50, 2297-2300 (2007). •• Describes the discovery of alogliptin. (Pubitemid 46799241)
23. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher R. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur. J. Pharmacol. 589, 306-314 (2008).
24. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase-IV in the treatment of Type 2 diabetes mellitus. Curr. Opin. Pharmacol. 4, 589-596 (2004).
25. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents b cell glucolipotoxicity. Diabetologia 47, 806-815 (2004). (Pubitemid 38756992)
26. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47(3), 357-366 (2004). (Pubitemid 38491230)
27. Karim A, Fleck P, Hetman L et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10 June 2008. Diabetes 57(Suppl. 1), (2008) (Abstract 538-P).
28. Karim A, Fleck P, Harrell RE Jr et al. Effects of age, race, and gender on the pharmacokinetics and pharmacodynamics of alogliptin, a novel and highly selective dipeptidyl peptidase-4 inhibitor, in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2-5 April 2008. Clin. Pharmacol. Ther. 83(Suppl. 1), S13 (2008) (Abstract PI-14). •• Demonstrated that that are no clinically relevant differences in the effect of alogliptin on pharmacokinetics and pharmacodynamics as a result of age, race, or gender.
29. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications (Third Edition). Williams & Wilkins, Baltimore, MD, USA (1995).
30. Hirayama M, Matsuno K, Fujita T et al. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin in Japanese healthy male subjects. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10 June 2008. Diabetes 57(Suppl. 1), (2008) (Abstract 521-P).
31. Karim A, Kissling J, Munsaka M. Effect of food on absorption and pharmacokinetics of antidiabetic drug, alogliptin, in healthy subjects. Presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. Atlanta, GA, USA, 17-19 November 2008. AAPS J. 10(Suppl. 2), (2008) (Abstract 1761).
32. Karim A, Fleck P, Joseph M et al. No pharmacokinetic interaction between alogliptin benzoate (SYR-322) and pioglitazone hydrochloride. Presented at: American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22-26 June 2007. Diabetes 56(Suppl. 1), (2007) (Abstract 2117-PO).
33. Fleck P, Karim A, Harris S et al. Lack of effect of multiple doses of alogliptin benzoate (SYR-322) on the pharmacokinetics of glyburide in healthy subjects. Presented at: American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22-26 June 2007. Diabetes 56(Suppl. 1), (2007) (Abstract 2135-PO).
34. Covington P, Christopher R, Davenport M et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects. Presented at: American Diabetes Association 67th Scientific Sessions. Chicago, IL, USA, 22-26 June 2007. Diabetes 56(Suppl. 1), (2007) (Abstract 2136-PO).
35. Karim A, Copa A, Fleck P, Helland J, Munsaka M, Mekki Q. Effects of alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (Ortho-Novum® 1/35) in healthy adult female subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2-5 April 2008. Clin. Pharmacol. Ther. 83(Suppl. 1), S14, (2008) (Abstract PI-16).
36. Karim A, Chiselko P, Fleck P, Harris S, Munsaka M, Mekki Q. Lack of effect of cyclosporine on the single-dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2-5 April 2008. Clin. Pharmacol. Ther. 83(Suppl. 1), S13, (2008) (Abstract PI-15).
37. Karim A, Fleck P, Harris S, Weiss M, Zhang W, Mekki Q. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2-5 April 2008. Clin. Pharmacol. Ther. 83(Suppl. 1), S12 (2008) (Abstract PI-13).
38. Karim A, Harris S, Fleck P, Moore R, Zhang W, Mekki Q. Assessment of drug interaction between alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, and warfarin at steady state. Presented at: 36th Meeting of the American College of Clinical Pharmacology. San Francisco, CA, USA, 9-11 September 2007. J. Clin. Pharmacol. 47(9), 1207 (2007) (Abstract 106).
39. Karim A, Fleck P, Harris S, Munsaka M, Weiss M, Mekki Q. Assessment of drug interaction between alogliptin, a highly selective dipeptidyl peptidase-4 inhibitor, and atorvastatin in healthy subjects. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA, 2-5 April 2008. Clin. Pharmacol. Ther. 83(Suppl. 1), S14 (2008) (Abstract PI-17).
40. Fleck P, Christopher R, Covington P, Wilson C, Mekki Q. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with Type 2 diabetes. Presented at: American Diabetes Association 68th Scientific Sessions. San Francisco, CA, USA, 6-10 June 2008. Diabetes 57(Suppl. 1), (2008) (Abstract 479-P). • Demonstrates that alogliptin is efficacious and well tolerated in patients with Type 2 diabetes.
41. Exenatide (marketed as Byetta) information www.fda.gov/CDER/Drug/ infopage/ exenatide/default.htm (Accessed 13 April, 2009)
42. FDA Approves Once-Daily Januvia, the First and Only DPP-IV Inhibitor Available in the United States for Type 2 Diabetes. Merck and Co Inc. Press Release, 17 October (2006) www.glucagon.com/pdfs/ JanuviaFDAApprovalPressReleaseOct1706. pdf (Accessed October 13, 2009)
43. Galvus receives European approval as new treatment for Type 2 diabetes with broad range of indications. Novartis. Press Release, 28 September (2007) www.novartis.com/newsroom/mediareleases/ en/2007/1156607.shtml (Accessed October 13, 2009)
44. AstraZeneca and Bristol-Myers Squibb submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the treatment of Type 2 diabetes. AstraZeneca and Bristol-Myers Squibb. Press Release, 23 July (2008) www.drugs.com/nda/ onglyza-080723. html (Accessed October 13, 2009)
45. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the US. Takeda Pharmaceutical Co., Ltd. Press Release, 3 January 2008 www.takeda.com/press/article-28864. html (Accessed October 13, 2009)